C Arthur Paul News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from C arthur paul. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In C Arthur Paul Today - Breaking & Trending Today

Antiviral drug 'Clevira' repurposed for treatment of mild to moderate COVID-19 cases


Antiviral drug Clevira repurposed for treatment of mild to moderate COVID-19 cases
Photo: Pexels
Clevira, a drug primarily developed to treat dengue, has been repurposed as supportive treatment for mild to moderate COVID-19 cases, its manufacturer Apex Laboratories Private Limited said on Friday.
The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days. The drug has also proved to be safe on liver and kidney parameters, it said.
Clevira, an antiviral formulation, has received regulatory approval as a supportive treatment for mild to moderate COVID-19 cases, the Chennai-based pharmaceutical company said. ....

Tamil Nadu , C Arthur Paul , International Business , Indian Council For Medical Research , Apex Laboratories Private , Ayurvedic Sciences , Interdisciplinary Technical Review Committee , Central Council For Research , Government Medical College Omandurar , Apex Laboratories Private Limited , Government Estate , Indian Council , Medical Research , Central Council , Arthur Paul , Manager International Business , Apex Laboratories , Erythrocyte Sedimentation Rate , தமிழ் நாடு , சர்வதேச வணிக , இந்தியன் சபை க்கு மருத்துவ ஆராய்ச்சி , ஆயுர்வேத அறிவியல் , மைய சபை க்கு ஆராய்ச்சி , அரசு எஸ்டேட் , இந்தியன் சபை , மருத்துவ ஆராய்ச்சி ,

Antiviral drug 'Clevira' repurposed for treating mild to moderate COVID-19 patients


Antiviral drug Clevira repurposed for treating mild to moderate COVID-19 patients
The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days.
Share Via Email
  |  A+A A-
Beds lie inside an indoor stadium converted into COVID-19 treatment center for emergencies in the wake of the spike in the numbers of positive coronavirus cases in Srinagar. (Photo | AP)
By PTI
NEW DELHI: Clevira, a drug primarily developed to treat dengue, has been repurposed as supportive treatment for mild to moderate COVID-19 cases, its manufacturer Apex Laboratories Private Limited said on Friday.
The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days. ....

Tamil Nadu , C Arthur Paul , International Business , Indian Council For Medical Research , Apex Laboratories Private , Ayurvedic Sciences , Interdisciplinary Technical Review Committee , Central Council For Research , Government Medical College Omandurar , Apex Laboratories Private Limited , Government Estate , Indian Council , Medical Research , Central Council , Arthur Paul , Manager International Business , Apex Laboratories , Erythrocyte Sedimentation Rate , தமிழ் நாடு , சர்வதேச வணிக , இந்தியன் சபை க்கு மருத்துவ ஆராய்ச்சி , ஆயுர்வேத அறிவியல் , மைய சபை க்கு ஆராய்ச்சி , அரசு எஸ்டேட் , இந்தியன் சபை , மருத்துவ ஆராய்ச்சி ,

Clevira, an antiviral formulation received Government of India regulatory approval as a supportive treatment for mild to moderate COVID-19 cases


Share
Bhubaneswar: Apex Laboratories Private Limited, a Chennai based pharmaceutical company known for its cutting-edge research and innovation, introduces Clevira, an antiviral herbal formulation.
Clevira was developed primarily to treat dengue patients in 2017. Last year as the COVID-19 cases surged in the country, it was repurposed as supportive treatment for mild to moderate COVID symptoms. The product is available across India and is priced at Rs 11 per tablet.
A clinical trial was conducted on 100 people in May-June 2020 and the results were promising.
During the 30 days trial, conducted at Government Medical College, Omandurar Government Estate Chennai, after approval from the Tamil Nadu government, the selected 100 participants were randomized into 2 Groups with 50 patients in each: the control group comprised of patients diagnosed with SARS-CoV-2 infection received standard care treatment as per hospital regulation as well as the WHO/ICMR guidelines. The t ....

Tamil Nadu , Karthik Shanmugam , C Arthur Paul , Pvt Ltd , Apex Laboratories Pvt Ltd , Indian Council Of Medical Research , Government Medical College , International Business , Apex Laboratories Private , Disciplinary Technical Review Committee , Ayurvedic Sciences , Government Of India Ministry , Central Council For Research , Apex Laboratories Private Limited , Omandurar Government Estate Chennai , Executive Director , Manager International Business , Apex Laboratories , Erythrocyte Sedimentation Rate , Indian Council , Medical Research , Central Council , Interdisciplinary Technical Review Committee , தமிழ் நாடு , பிரைவேட் லிமிடெட் , உச்சம் ஆய்வகங்கள் பிரைவேட் லிமிடெட் ,